source
- Novo projects flat 2026 sales as CFO exits, marking an upgrade from prior expectationsNovo announced that its 2026 sales outlook will be flat, a shift from earlier growth expectations. The drugmaker also disclosed that its chief financial officer will be leaving the company, and a…
- Minghui Pharma sells Japanese rights to its Phase 3 thyroid eye disease drug for $110 million upfrontMinghui Pharmaceutical, a Shanghai‑based biotech, has agreed to transfer the Japanese commercial rights for its late‑stage thyroid eye disease candidate to a specialty pharmaceutical company. The…